DAX24.362 -0,3%Est505.649 +0,1%MSCI World4.344 +0,4%Top 10 Crypto16,67 +1,2%Nas22.854 ±0,0%Bitcoin102.383 -0,4%Euro1,1739 +0,2%Öl64,40 +0,1%Gold3.874 +0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Tesla A1CX3T Siemens Energy ENER6Y HENSOLDT HAG000 Plug Power A1JA81 Alibaba A117ME Novo Nordisk A3EU6F thyssenkrupp 750000 BASF BASF11 Lufthansa 823212 Deutsche Telekom 555750 Bayer BAY001
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fällt zurück -- US-Börsen höher -- BMW steigert US-Absatz deutlich -- Investoren wollen Billionen-Vergütung für Tesla-CEO Musk stoppen -- Plug Power, IONOS, Boeing, Roche im Fokus
Top News
Palantir-Aktie verliert: US-Armee bemängelt hohe Risiken bei neuem Kommunikationssystem Palantir-Aktie verliert: US-Armee bemängelt hohe Risiken bei neuem Kommunikationssystem
S&P 500-Papier Morgan Stanley-Aktie: So viel hätten Anleger an einem Morgan Stanley-Investment von vor 5 Jahren verdient S&P 500-Papier Morgan Stanley-Aktie: So viel hätten Anleger an einem Morgan Stanley-Investment von vor 5 Jahren verdient
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Günstig global investieren mit unserem neuen FINANZEN.NET MSCI WORLD ETF - nur 0,12 % TER. Jetzt informieren!

Ionis Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
58,22 EUR +0,48 EUR +0,83 %
STU
68,17 USD -0,23 USD -0,34 %
BTT
Ionis Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.8,95 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2ACMZ

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4622221004

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIONS

Ionis Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireIonis to hold fourth quarter and full year 2023 financial results webcast
PR NewswireIonis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
PR NewswireIonis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
PR NewswireWAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
PR NewswireIonis to present at 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireIonis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
PR NewswireIonis announces the appointment of Michael Yang to Board of Directors
PR NewswireIonis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
PR NewswireIonis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis reports third quarter 2023 financial results
PR NewswireIonis to hold third quarter 2023 financial results webcast
PR NewswireIonis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
PR NewswireEplontersen Phase 3 results published in JAMA show consistent and sustained benefit
PR NewswireIonis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
PR NewswireIonis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
PR NewswireIonis to host investor and analyst day event
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis reports second quarter 2023 financial results
PR NewswireIonis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
PR NewswireIonis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
PR NewswireIonis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
PR NewswireIonis to hold second quarter 2023 financial results webcast
PR NewswireEplontersen continued to show improvement in ATTRv-PN through 85 weeks
PR NewswireIonis to present at upcoming investor conference
PR NewswireNew data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
PR NewswireIonis prices private placement of convertible senior notes
PR NewswireIonis announces proposed private placement of convertible notes
PR NewswireIonis announces positive donidalorsen late-stage clinical progress in HAE
PR NewswireIonis to host 2023 virtual Annual Meeting of Stockholders
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis reports first quarter 2023 financial results
PR NewswireFDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
PR NewswireEplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
PR NewswireIonis to hold first quarter 2023 financial results webcast
PR NewswireNew data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
PR NewswireIonis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
PR NewswireIonis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

Ionis Pharmaceuticals News

Ionis Pharmaceuticals News: auf dieser Seite finden Sie alle Ionis Pharmaceuticals News und Nachrichten zur Ionis Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ionis Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ionis Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.